Weight Loss Study Comparing Two Doses of CagriSema
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether a new combination medication called CagriSema (in two different doses) helps people with obesity lose weight. You may qualify if you're 18 or older, have a BMI of 35 or higher, and either don't have type 2 diabetes or have it well-controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- BMI (body mass index) of 35.0 or higher
- No significant weight change (more than 5%) in the 3 months before screening
- Haven't used GLP-1 medications (like Ozempic, Wegovy) or amylin medications in the past 6 months
- If you don't have diabetes: blood sugar (HbA1c) below 6.5%; if you have diabetes: HbA1c below 10%
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tests a new medication called CagriSema to understand how it affects muscle health while helping people lose weight. You'll be in the trial for about a year, and researchers will monitor your muscle function and body composition.
This study compares two different versions of an investigational weight-loss medication (cagrilintide) against a placebo to see which is more effective and safe for people with excess weight. Participation involves receiving injections and regular check-ins to monitor your progress.
This trial tests two new medicines (cagrilintide and CagriSema) to see if they help children and teens lose weight. It's for young people who have tried lifestyle changes without enough success.
This trial tests a new medicine Zenagamtide to see if it helps people with excess weight lose more weight than Semaglutide, an existing weight loss drug. You may join if you are an adult with overweight or obesity but do not have diabetes.
This study tests a nasal spray containing semaglutide (a GLP-1 receptor agonist) to see if it helps adults who are overweight or obese lose weight. It may be an option if you have a BMI between 27 and 35 and have not used other weight loss medications recently.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.